In leukemia and breast cancer CSCs, overexpression of BCL-2 and BCL-XL has been associated with resistance to chemotherapy, enabling CSCs to evade apoptosis and sustain tumor progression [63, 64]. This evidence concerns the gene BCL2 and neoplasm.